Börskollen
Pressmeddelanden från Biohit
09 aug 2023 08:30
BiohitBIOHIT GROUP HALF YEAR FINANCIAL REPORT 202315 jun 2023 13:00BiohitConstitutive meeting of Biohit Oyj’s Board of Directors14 jun 2023 17:00BiohitDecisions of the Annual General Meeting of Biohit Oyj24 maj 2023 11:00BiohitNotice of Biohit Oyj’s Annual General Meeting30 mar 2023 10:00BiohitBiohit Oyj B-shares Subscribed with Stock Options I 2021A and I 2022A22 mar 2023 08:30BiohitPublication of Biohit Oyj Renumeration Report 202222 mar 2023 08:30BiohitPublication of Biohit Oyj Annual Report 202215 feb 2023 08:30BiohitBIOHIT GROUP FINANCIAL STATEMENT RELEASE 202215 dec 2022 13:00BiohitChanges to Biohit Oyj’s management: Change of R&D Director07 dec 2022 14:00BiohitBiohit Oyj - Managers' Transactions - Hendolin07 dec 2022 14:00BiohitBiohit Oyj - Managers' Transactions - Sorvo30 nov 2022 13:00BiohitBiohit Oyj’s Financial Reporting and Annual General Meeting in 202329 nov 2022 13:00BiohitBiohit Oyj Board of Directors decided on new option scheme19 sep 2022 12:00BiohitStrong scientific Support for Biohit’s GastroPanel in International Consensus Report07 sep 2022 12:00BiohitBiohit GastroPanel enters into global market by co-operation with Randox06 sep 2022 13:00BiohitChanges to Biohit Oyj’s management02 sep 2022 11:00BiohitChange of CEO at Biohit Oyj22 aug 2022 12:30BiohitChanges to Biohit Oyj’s management09 aug 2022 12:00BiohitDyspeptic symptoms need early attention- domestic innovations GastroPanel®, ColonView-FIT® and Acetium® will help03 aug 2022 08:30BiohitPositive profit warning: Biohit Oyj raises its guidance for 2022 and publishes preliminary information about the result of the first half-year16 jun 2022 08:30BiohitConstitutive meeting of Biohit Oyj’s Board of Directors15 jun 2022 15:00BiohitDecisions of the Annual General Meeting of Biohit Oyj25 maj 2022 13:00BiohitNotice of Biohit Oyj’s Annual General Meeting10 maj 2022 10:00BiohitPublication of Biohit Oyj Renumeration Report 202130 mar 2022 08:30BiohitPublication of Biohit Oyj Annual Report 202110 mar 2022 09:00BiohitBiohit Oyj Extraordinary general meeting and board of directors meeting decisions15 feb 2022 09:00BiohitNEW RECOMMENDATION BY THE MINISTRY OF HEALTH OF THE RUSSIAN FEDERATION: All patients with suspected gastritis should be examined by Pepsinogen I, Pepsinogen II and Gastrin-17 biomarkers.09 feb 2022 13:00BiohitNotice of Biohit Oyj's extraordinary general meeting08 feb 2022 13:00BiohitBiohit has settled the dispute concerning a breach of the patent license agreement and therefore specifies its financial guidance for 202118 jan 2022 14:00BiohitBiohit Oyj Managers' Trancactions - Elomaa18 jan 2022 14:00BiohitBiohit Oyj - Managers' Transactions - Siltala18 jan 2022 14:00BiohitBiohit Oyj - Managers' Transactions - Söderström18 jan 2022 14:00BiohitBiohit Oyj - Managers' Transactions - Patrakka18 jan 2022 14:00BiohitBiohit Oyj - Managers' Transactions - Mäki18 jan 2022 14:00BiohitBiohit Oyj - Managers' Transactions - Hahtela13 jan 2022 13:30BiohitBiohit Oyj’s Financial Reporting and Annual General Meeting in 202214 dec 2021 09:00BiohitRecent clinical validation study confirms the accuracy of the new-generation GastroPanel® test in diagnosis of atrophic gastritis and Helicobacter pylori infection.09 dec 2021 13:00BiohitBiohit Oyj Board of Directors decided on new option scheme
BiohitBiohitBiohitBiohitBiohitBiohitBiohitBiohitBiohitBiohitBiohitBiohitBiohitBiohitBiohitBiohitBiohitBiohitBiohitBiohitBiohitBiohitBiohitBiohitBiohitBiohitBiohitBiohitBiohitBiohitBiohitBiohitBiohitBiohitBiohitBiohitBiohitBiohit